For the third straight season, Cleveland Cavaliers center Anderson Varejao will bow out to a season ending injury. On Monday, the Cavaliers announced that the center will miss the remainder of the season due to the discovery of a blood clot in his lung. The blood clot, which occurred when Varejao had surgery to repair a torn hamstring, will put him on blood thinning medicine for the next three months. This latest setback will surely end all trade rumors regarding the Brazilian.
Prior to his injuries, Varejao was having the best season of his NBA career. In 25 games, Varejao averaged 14.1 points and 14.4 rebounds in 36 minutes per game. Both of his scoring and rebounding averages are double his career averages in the respective categories.
In the release, Cavaliers general manager Chris Grant had this to say about Varejao’s blood clot: “Clearly, our players’ health is our top concern and we are disappointed for Anderson, and his family. We know what a competitor he is and how much he wants to be on the court helping his teammates. In the meantime, he has our full support, and we look forward to welcoming him back as he recovers.’
For the Cavaliers as a team, this is a major blow. Currently at second to last in the Eastern Conference, there was a glimmer of hope that Varejao could return in a few months and help save a lost season. Any hopes of the Cavaliers staying out of the cellar now falls on the shoulder of point guard Kyrie Irving, who has also missed time this season due to injury. But without their heart and soul, it is hard to think that the Cavaliers have any chance of improving very much. In my mind, this latest setback means that, come June, the Cavaliers will again be picking near the top of draft.